Serina Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 3, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	18	47	-	-	-
Enterprise Value	13	55	-	-	-
Last Close Price	1.67	5.01	-	-	-
PS Ratio	155.27	840.25	-	-	-
PB Ratio	11.30	92.63	-	-	-
P/TBV Ratio	-	73.41	-	-	-
EV/Sales Ratio	110.15	990.71	-	-	-
Debt / Equity Ratio	2.12	0.91	0.90	-0.77	1.19
Net Debt / Equity Ratio	-3.28	-6.32	-0.95	-0.55	-2.73
Net Debt / EBITDA Ratio	0.24	0.21	2.73	-0.58	0.57
Net Debt / FCF Ratio	0.32	0.19	1.32	-0.61	0.39
Asset Turnover	0.01	0.01	0.64	0.44	-
Quick Ratio	0.98	1.55	5.39	1.22	3.53
Current Ratio	1.31	2.40	5.39	1.25	3.58
Return on Equity (ROE)	-	-485.36%	594.25%	-	-
Return on Assets (ROA)	-137.85%	-124.04%	-19.46%	-105.01%	-
Return on Capital Employed (ROCE)	-604.00%	-357.30%	-20.30%	-540.10%	-110.80%
Earnings Yield	-104.39%	-23.68%	-	-	-
FCF Yield	-92.02%	-36.47%	-	-	-
Buyback Yield / Dilution	-72.47%	-0.11%	-242.70%	-0.01%	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q